Ionis Pharmaceuticals (IONS) 10-K2011 FY Annual report

Filed: 29 Feb 12, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman V good

New words: AAA, AAT, AATD, abiraterone, afforded, ALT, amyloid, antitrypsin, appetite, Australia, authoritative, autosomal, Beta, Biogen, biomarker, bond, brand, brett, cancel, cancellation, Cardiology, cardiomyopathy, Catenin, child, childhood, children, coherence, coincide, College, consecutive, Convention, cord, country, cure, cycle, denying, devastating, diacylglycerol, diminished, discretion, District, dollar, downgrade, dyslipidemia, effort, EMA, enjoining, enlarge, expended, FAC, FAP, flexible, France, gather, gathered, Germany, healing, hope, huntingtin, hyperglycemia, Idec, illustrated, inactive, India, infancy, injunction, intent, internationally, irregular, irreversible, Italy, Japan, jurisdiction, Kingdom, KYNAMRO, lapse, lawsuit, legacy, lifestyle, LNP, manifest, metformin, misfolded, monia, motion, multifaceted, muscle, NASH, necessity, neovascularization, nephropathy, nerve, nonalcoholic, occasion, optical, outlook, owing, pace, package, paragraph, pediatric, penetration, peripheral, perpetuity, plasma, plazomicin, polyneuropathy, possession, precursor, prefilled, problem, profound, prosecution, qualitative, revert, sanofi, School, simultaneously, Southern, sovereign, SPA, Spain, strike, succumb, superficial, Symposium, symptom, syringe, Tekmira, titled, tomography, top, tract, trend, uncured, Union, unnecessary, unsuccessfully, urinary, vigorously, VII, volume, voluntarily, wound

Removed: academic, Affirmative, alleging, antagonism, antagonist, antagonize, Appeal, aptamer, Archemix, asthma, Atugen, begun, blinded, blocking, Bruker, carried, clear, combat, compensate, consolidating, Counterclaim, County, coupled, cutting, decided, Dharmacon, dimarchi, distributed, Division, edge, eliminated, enabling, enhancing, excluded, excretion, executed, expansive, expensed, fill, formal, gained, Gehrig, grow, guiding, hardening, hemoglobin, infusing, infusion, inhaled, intercompany, Internet, justification, led, letter, leveraging, Lou, mammalian, man, mediation, metabolism, Middlesex, modulating, neoglycoside, notified, observe, original, originated, overhead, patented, Peter, plc, positioned, potently, prime, promote, pump, reinstated, reinstatement, remove, rentable, repaid, repayment, replication, respiratory, revoked, segregation, shape, Silence, stand, stemming, superior, surface, toolbox, transporter, typical, underserved, unopposed, unregistered, unsatisfactory, unsuccessful, urine, USA, validated, yielded

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

IONS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statements (Form S-3 Nos. 33-55790, 33-72124, 33-75068, 33-96138, 333-71911, 333-90811, 333-38844, 333-71116, 333-71176, 333-89066, 333-89626, 333-128156, 333-130639, 333-134380, 333-141447, 333-151076 and Form S-8 Nos. 33-42356, 33-42970, 33-51236, 33-54840, 33-58450, 33-75150, 33-90780, 333-05825, 333-55683, 333-40336, 333-59296, 333-91572, 333-106859, 333-116962, 333-125911, 333-133853, 333-142777, 333-151996, 333-160269, 333-168674, 333-176136) of Isis Pharmaceuticals, Inc. and in the related Prospectus of our reports dated February 29, 2012, with respect to the consolidated financial statements of Isis Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Isis Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2011.

	/s/ ERNST & YOUNG LLP

San Diego, California
February 29, 2012